Reason for request
Assessment of change of dose permitting use in children aged between 2 and 16.
Clinical Benefit
| Substantial |
The clinical benefit provided by DUROGESIC in children is substantial. |
Clinical Added Value
| Comments without ASMR value |
DUROGESIC has previously been recognised by the Transparency Committee as providing actual benefit in adults, and it provides the same benefit for children over 2. |
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
ny70BUwsVc2Ytnk5
